STOCK TITAN

Woodline Partners discloses 4.8M-share Zevra Therapeutics (ZVRA) ownership position

(Moderate)
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Woodline Partners LP, a Delaware limited partnership and investment adviser to Woodline Master Fund LP and Woodline Spire Master Fund LP, reported its beneficial ownership of common stock of Zevra Therapeutics, Inc. on an amended Schedule 13G. Woodline Partners is deemed to beneficially own 4,785,771 shares of Zevra common stock, representing 8.1% of the class, based on 59,115,084 shares outstanding as of May 1, 2026. Woodline has sole voting and dispositive power over these shares and no shared power. Woodline Master Fund LP has the right to receive or direct the receipt of dividends and sale proceeds related to the reported shares.

Positive

  • None.

Negative

  • None.
Beneficially owned shares 4,785,771 shares Common stock of Zevra Therapeutics beneficially owned by Woodline Partners
Ownership percentage 8.1% Percent of Zevra Therapeutics common stock class reported by Woodline Partners
Shares outstanding baseline 59,115,084 shares Zevra common shares outstanding as of May 1, 2026 used to calculate 8.1%
Sole voting power 4,785,771 shares Shares for which Woodline Partners has sole power to vote or direct the vote
Sole dispositive power 4,785,771 shares Shares for which Woodline Partners has sole power to dispose or direct disposition
beneficial owner regulatory
"the beneficial owner of the shares of Common Stock reported herein"
A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.
sole voting power regulatory
"Sole Voting Power 4,785,771.00"
Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.
sole dispositive power regulatory
"Sole Dispositive Power 4,785,771.00"
Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.
percent of class regulatory
"Percent of class: 8.1%"
Percent of class is the portion of a specific category of securities—such as a company’s common shares, preferred shares, or a bond series—that takes part in or approves a corporate action (vote, consent, tender, etc.). Investors watch this number because it reveals how much support or opposition exists within that particular shareholder group; like counting how many members of a club back a proposal, it can determine whether a plan passes or how influence is distributed.
investment adviser financial
"the investment adviser to Woodline Master Fund LP and Woodline Spire Master Fund LP"
An investment adviser is a person or firm that professionally manages money and gives recommendations about buying, selling, or holding investments. Like a financial coach or guide, they have a legal duty to act in a client's best financial interest, so their advice, fees and potential conflicts can directly affect returns and risk — making their role important for investors who want informed, accountable help with portfolios.

FAQ

What percentage of Zevra Therapeutics (ZVRA) does Woodline Partners report owning?

Woodline Partners reports beneficial ownership of 8.1% of Zevra Therapeutics’ common stock. This percentage is based on 59,115,084 shares outstanding as of May 1, 2026, as stated in Zevra’s Form 10-Q.

How many Zevra Therapeutics (ZVRA) shares does Woodline Partners control?

Woodline Partners reports beneficial ownership of 4,785,771 Zevra Therapeutics common shares. It has sole voting and sole dispositive power over all of these shares and no shared voting or dispositive power.

Which entities are involved in Woodline’s Zevra Therapeutics (ZVRA) position?

The position is reported by Woodline Partners LP, investment adviser to Woodline Master Fund LP and Woodline Spire Master Fund LP. The Woodline Funds directly hold the Zevra shares, with Woodline Partners filing as the reporting person.

Who can receive dividends and sale proceeds from the Zevra Therapeutics (ZVRA) shares?

According to the filing, Woodline Master Fund LP has the right to receive, or direct the receipt of, dividends and sale proceeds from the Zevra Therapeutics common shares reported as beneficially owned.

What is the share count used to calculate Woodline’s 8.1% stake in Zevra (ZVRA)?

The 8.1% ownership percentage is calculated using 59,115,084 Zevra common shares outstanding as of May 1, 2026, as reported in Zevra’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026.

Does Woodline Partners share voting control over Zevra Therapeutics (ZVRA) shares with others?

No. The filing states that Woodline Partners has sole voting power and sole dispositive power over 4,785,771 Zevra shares and reports zero shared voting or dispositive power.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates





488445206

(CUSIP Number)
06/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G



Woodline Partners LP
Signature:/s/ Erin Mullen
Name/Title:By: Erin Mullen, General Counsel & Chief Compliance Officer
Date:08/14/2026